Puma Biotechnology, Inc. (PBYI) is a publicly traded biopharmaceutical company that specializes in developing and commercializing innovative novel therapeutics for the treatment of cancer. Founded in 2010 by Alan H. Auerbach, a seasoned professional with significant industry experience in oncology drug development, Puma Biotechnology is headquartered in Los Angeles, California.
Puma Biotechnology mirrors its founder’s vision of leveraging science and innovation to advance cancer treatment. Its lead drug product is Nerlynx (neratinib), an oral tyrosine kinase inhibitor that targets the human epideral growth factor receptor 2 (HER2) protein. Approved by the U.S Food and Drug Administration (FDA) in 2017, Nerlynx is primarily used as an extended adjuvant treatment for adult patients with early-stage HER2 overexpressed/amplified breast cancer.
What sets Puma Biotechnology apart in the pharmaceutical industry is its purely focused commitment to cancer therapies, specifically targeting HER2+ breast cancer. This condition affects approximately 20% of all breast cancer patients worldwide and Puma's dedicated research and development strategies signify an important contribution to addressing the unmet medical needs of these patients.
This research-driven company is actively involved in several clinical trials aimed at expanding the therapeutic indications of Nerlynx, not only within the breast cancer space but also for other types of cancers that overexpress or have a mutation in the HER2 gene. The company focuses on innovation and consistent growth all while placing value on patient safety, efficacy, and enhanced quality of life.
Moreover, Puma’s dedication to cancer care extends to practitioner education and patient assistance. It provides healthcare professionals with comprehensive resources and support tools to better understand the optimal use of its medicine. For patients, the company facilitates access to therapy through its Puma Patient Lynx program, which offers financial assistance to eligible individuals.
Despite regulatory pressures and stringent industry standards which demand constant vigilance and commitment to quality compliance, Puma Biotechnology has displayed commendable resilience and adaptability. Listed on the NASDAQ Global Select Market under the ticker symbol "PBYI", the company has demonstrated a consistent ability to successfully navigate through the complex landscape of drug development.
In conclusion, Puma Biotechnology embodies a relentless pursuit of revolutionary drug therapies to ease the burden of cancer patients worldwide. Be it through the development of therapeutic solutions, the provision of resources to enhance healthcare practices or providing financial assistance, Puma is a key player dedicated to making a significant impact in the fight against cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Puma Biotechnology (PBYI) has initiated the phase II ALISCA-Lung2 study to evaluate its pipeline candidate, alisertib, in combination with paclitaxel for treating advanced small cell lung cancer. The study, expected to enroll around 50 patients, will assess the safety and tolerability of the combination therapy. PBYI is also exploring alisertib for hormone receptor-positive breast cancer and expects updated data from the ALISCA-Breast1 study in Q4 2026.
Puma Biotechnology director Wilson Troy Edward sold 5,000 shares of the company's stock at $9.10 per share on September 14, 2026. This transaction reduced his stake by approximately 8.4%, leaving him with 54,750 shares. The sale provides insight into his insider activity and remaining equity in the company.
Puma Biotechnology (PBYI) is leveraging its established breast cancer drug, NERLYNX, to fund the development of its pipeline, particularly alisertib, which is in Phase 2 trials for oncology. The company currently maintains positive cash flow and a healthy balance sheet, supporting its R&D efforts. While alisertib presents a speculative but promising next oncology franchise, the main risk lies in its successful development before generic competition for NERLYNX emerges around 2030.
Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number of shares recently. Institutional ownership remains high at 61.29%.
Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. Puma is also progressing with its clinical trials for alisertib in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer, and is actively seeking business development opportunities to diversify its portfolio.